A Phase 3 4-week Multicenter Randomized Double-blind Placebo-controlled Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure

Brief description of study

This study will look at whether an investigational drug called TD-9855 works and how safe it is for treating symptomatic neurogenic orthostatic hypotension (snOH) in people with Parkinson's disease (PD), multiple system atrophy (MSA) or pure autonomic failure (PAF). It will also look at the effects of TD-9855 on participants' general wellbeing. TD-9855 will be referred to throughout the rest of the document as the 'study drug'. Investigational means that it is has not yet been approved for use outside of research studies like this one.


Clinical Study Identifier: s18-01562
ClinicalTrials.gov Identifier: NCT03750552
Principal Investigator: Jose Alberto Palma Carazo
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.